Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Agilon Health Inc (NYSE: AGL) closed at $1.25 in the last session, up 1.63% from day before closing price of $1.23. In other words, the price has increased by $1.63 from its previous closing price. On the day, 7.95 million shares were traded. AGL stock price reached its highest trading level at $1.27 during the session, while it also had its lowest trading level at $1.18.
Ratios:
We take a closer look at AGL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.02.
On April 25, 2025, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $5.
Bernstein Upgraded its Mkt Perform to Outperform on April 08, 2025, while the target price for the stock was maintained at $8.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when McLoughlin Karen bought 25,000 shares for $2.20 per share. The transaction valued at 55,085 led to the insider holds 73,166 shares of the business.
Battaglia Silvana bought 25,062 shares of AGL for $50,269 on Dec 11 ’24. The Director now owns 66,144 shares after completing the transaction at $2.01 per share. On Nov 25 ’24, another insider, MCKENZIE DIANA, who serves as the Director of the company, bought 12,500 shares for $2.28 each. As a result, the insider paid 28,474 and bolstered with 51,319 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 518028768 and an Enterprise Value of 232400944. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.09 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 0.039 whereas that against EBITDA is -0.669.
Stock Price History:
The Beta on a monthly basis for AGL is 0.12, which has changed by -0.7276689 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, AGL has reached a high of $6.08, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is -34.70%, while the 200-Day Moving Average is calculated to be -55.38%.
Shares Statistics:
According to the various share statistics, AGL traded on average about 9.33M shares per day over the past 3-months and 23172050 shares per day over the past 10 days. A total of 414.28M shares are outstanding, with a floating share count of 304.05M. Insiders hold about 26.63% of the company’s shares, while institutions hold 72.70% stake in the company. Shares short for AGL as of 1753920000 were 18921380 with a Short Ratio of 2.03, compared to 1751241600 on 20836728. Therefore, it implies a Short% of Shares Outstanding of 18921380 and a Short% of Float of 7.470000000000001.
Earnings Estimates
The company has 10.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.08 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$0.34 and -$0.89 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.38, with 14.0 analysts recommending between -$0.16 and -$0.53.
Revenue Estimates
According to 17 analysts, the current quarter’s revenue is expected to be $1.44B. It ranges from a high estimate of $1.53B to a low estimate of $1.35B. As of the current estimate, Agilon Health Inc’s year-ago sales were $1.45BFor the next quarter, 17 analysts are estimating revenue of $1.47B. There is a high estimate of $1.56B for the next quarter, whereas the lowest estimate is $1.4B.
A total of 19 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $6.02B, while the lowest revenue estimate was $5.7B, resulting in an average revenue estimate of $5.83B. In the same quarter a year ago, actual revenue was $6.06BBased on 19 analysts’ estimates, the company’s revenue will be $6.3B in the next fiscal year. The high estimate is $7.14B and the low estimate is $5.77B.
